Document Classification

Section Type: METHODS

Text: A total of 855 patients with histologically verified resected cutaneous melanoma in AJCC stage IIb (T4 N0 M0) or stage III (Tx N1-3 M0) were randomised to : Arm A : observation only (n = 284) ; Arm B : 1-year treatment : induction : IFN alfa-2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks, maintenance : IFN alfa-2b, 10 MU (flat dose), SC, 3 days/week for 12 months (n = 285) ; or Arm C : 2 years of same treatment as Arm B. HRQoL was assessed using The European Organisation for Research and Treatment of Cancer Core Questionnaire (EORTC QLQ-C30) before randomisation and at 8 pre-defined time-points during 2 years.